Abstract. This study compared in vitro dissolution characteristics and other quality measures of different amoxicillin, metronidazole, and zidovudine products purchased in the Americas to a comparator pharmaceutical product (CPP). These three drugs are classified as Biopharmaceutics Classification System Class I drugs with the possibility that dissolution findings might be used to document bioequivalence. All investigated zidovudine products were found to be in vitro equivalent to the CPP. Only 3 of 12 tested amoxicillin products were found to be in vitro equivalent to the CPP. None of the tested metronidazole products were in vitro equivalent to the CPP. These findings suggest but do not confirm bioinequivalence where in vitro comparisons failed, given that an in vivo blood level study might have confirmed bioequivalence. At times, identifying a CPP in one of the selected markets proved difficult. The study demonstrates that products sold across national markets may not be bioequivalent. When coupled with the challenge of identifying a CPP in different countries, the results of this study suggest the value of an international CPP as well as increased use of BCS approaches as means of either documenting bioequivalence or signaling the need for further in vivo studies. Because of increased movement of medicines across national borders, practitioners and patients would benefit from these approaches.
INTRODUCTION
The World Health Organization (WHO) vision for essential medicines is "that people everywhere [should] have access to the essential medicines they need; that the medicines are safe, effective, and of assured quality; and that they are prescribed and used rationally" (1) . Today, this remains a challenge in many developing countries partly because of counterfeit drugs (2) but also because of a lack of sufficient regulatory oversight to ensure drug quality (3, 4) . Multisource (generic) medicines help to make drug therapy more likely affordable, but they must be interchangeable, i.e., therapeutically equivalent to an innovator product. The pharmaceutical and regulatory criteria for interchangeable multisource medicines in the US market are described in the Orange Book published by the Food and Drug Administration (FDA) (5) and in many other regulatory documents.
Generally, the first step in generic development in the USA is to create a product that is pharmaceutically equivalent to the Reference Listed Drug (RLD) specified in the Orange Book. FDA defines pharmaceutical equivalence as a drug product that:
1. contains the same active ingredient(s) and salt form, 2. uses the same dosage form and route of administration, and 3. has the same strength or concentration as the RLD.
The generic drug manufacturer then conducts relative bioavailability (bioequivalence) studies comparing the RLD and the proposed generic equivalent (5), typically using the listed innovator product. Clinical bioequivalence testing to establish therapeutic equivalence can be relatively expensive and time consuming. An alternative is dissolution testing to establish in vitro bioequivalence (6) . This approach can be used for certain highly soluble drugs according to the Biopharmaceutics Drug Classification System (BCS) (7) . Today, the science and validity of the BCS are well established, and many Electronic supplementary material The online version of this article (doi:10.1208/s12248-012-9350-9) contains supplementary material, which is available to authorized users. biowaiver extensions have been proposed by the scientific community and some have been approved by regulatory bodies (8) (9) (10) (11) . Note: a dichotomy in nomenclature exists between WHO and US documents wherein bioequivalence in WHO terminology refers to a comparative blood level (pharmacokinetic studies). The USA allows a broader definition of the types of bioequivalence (BE) studies (also comparative clinical, pharmacodynamic, and in vitro studies). This paper uses the US terminology so that pharmaceutical equivalence and bioequivalence (with the several options available) equals therapeutic equivalence (12) . WHO also uses the term comparator pharmaceutical product (CPP) instead of RLD.
Based on the BCS, WHO developed the Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms (6) . This document outlines the criteria under which in vitro testing can replace in vivo bioequivalence testing. In brief, the proposal applies to drug products that contain BCS Class 1 or 3 drugs and also to some Class 2 drugs. A generic tested in three different media must have dissolution profiles that are similar to those of the comparator product. The aim of WHO's proposal is to enable regulatory agencies in developing countries to approve generics based on comparative in vitro studies instead of bioequivalence studies (13) . The WHO proposal suggests using a well-established drug product, usually the innovator's product, as the CPP.
The current study identified the RLD or another suitable product listed in the Orange Book as the CPP (5). FDA approved these products because they were shown to be safe and effective when used as directed. Furthermore, FDA requires that any postapproval manufacturing change must be shown by a manufacturer to maintain therapeutic equivalence to the prechange product (5) .
The goal of the study reported here was to examine and document product performance of three widely used drug products marketed in different countries of the Americas. The study investigated the dissolution behavior of different amoxicillin, metronidazole, and zidovudine products purchased in those countries. The generic products were compared to the CPP and to each other to determine if they met in vitro bioequivalence criteria (8) . The study hypothesis was that the different drug products would meet the criteria for in vitro equivalence. The dissolution studies presented in this report repeat the type of studies conducted by Blume et al. with the difference that BCS criteria were incorporated into the study design (14) (15) (16) . With the understanding arising from the BCS, the studies in the present report can also signal bioequivalence, which is termed in vitro equivalence where applicable. In vivo studies were not performed in this study. Thus when in vitro studies did not signal bioequivalence, further clinical studies might have confirmed this conclusion.
METHODS

Chemicals
Amoxicillin Reference Standard (RS) (J0C043), Metronidazole RS (JOC316), and Zidovudine RS (HOF263) were received from US Pharmacopeia (USP, Rockville, MD). Acetonitrile, potassium phosphate, sodium acetate, and sodium hydroxide were purchased from Caledon (Georgetown, ON). Hydrochloric acid, potassium hydroxide, and phosphoric acid were received from Fisher Scientific (Bridgewater, NJ). All chemicals were USP or American Chemical Society grade.
Weight Variation
The weight of 18 capsules or tablets was recorded for each product tested. The weight variation was calculated as standard deviation (s) using Eq. 1:
where X i are individual weights, X is the mean of all weights, and n is the number of samples measured. Weight variation was recorded to assess whether any analytical data would show abnormally high or low values linked to an overdosing or underdosing of the test units.
Content Uniformity
The chemical assay was performed for each CPP according to its USP monograph. If required by the CPP's USP monograph, Uniformity of Dosage Units <905> tests were performed. Analysts evaluated the content uniformity using an Excel spreadsheet published by USP (17).
Media Preparation
Simulated gastric fluid (SGF), acetate buffer pH 4.5 USP, and simulated intestinal fluid (SIF) were prepared according to instructions in USP Test Solutions. All media were prepared without enzymes. The density of each medium was determined at room temperature using a 1-L volumetric flask.
Media were deaerated in the following manner: 1 L dissolution medium was heated above 41°C and filtered through a 0.45-μm filter (Fisher General Filtration MEC filter, 0.45 μm) into a media bottle that was immersed in a Branson Model 8200 ultrasonic bath (Brandson, Danbury, CT). Table I lists all amoxicillin products tested, Table II all  metronidazole products, and Table III all ziduvudine products. All products were tested at least 12 months before their stated expiry date.
Dissolution Test
A VK 7020 dissolution tester with six vessels and a VK 8000 autosampler station (Varian Inc., Carey, NC) was used. USP Apparatus 2 (paddle) at 75 rpm and 900 mL media were used for all tests. Preheated and degassed dissolution medium was weighed into each dissolution vessel individually. The filling process was performed with caution to avoid inclusion of air into the medium. The test was started after the temperature in all vessels was confirmed.
USP sinkers were used for the capsule products. Sample concentrations were determined via high-performance liquid chromatography (HPLC) analysis: 1.25 mL medium was withdrawn from each vessel at each time point and filtered (Full Flow Filters, Varian Inc.), and 1 mL was transferred into a 2.5-mL vial for quantitation. The remaining fluid was discarded, and media were not replaced in the vessels after sampling. Drug concentration was corrected by calculation for the withdrawn volume. The sampling time points were 10, 15, 20, 30, 45, and 60 min.
Analytical Quantitation
The amount of dissolved drug was determined using an HPLC method. The system comprised a system controller SCL-10A, two LC-10A pumps, an autosampler SIL-10ADvp, a diode-array detector SPD-M10Avp, and data-acquisition software EX Start 7.4 (Shimadzu, Columbia, MS). The mobile phases were degassed before use. The flow rate was 1 mL/min, and the retention time for each drug was about 2 to 2.5 min with a run time of 3 to 3.5 min. Ten-microliter samples were directly injected without dilution.
Amoxicillin
The analytical quantitation of the dissolution samples was modified from the USP monograph for amoxicillin tablets in order to achieve a shorter retention time and better linearity over the expected concentration range of 3.75% to 120% of labeled content in 900 mL of medium. The HPLC assay used the following conditions: UV detection took place at 219 nm, and the analytical column was an RP 18 LiChrospher 100 column (12.5×4 mm) (Merck, Darmstadt, DE) with guard column. The mobile phase was buffered to pH 5.0 with acetonitrile 5%. The buffer composition consisted of 6.8 g KH 2 PO 4 added to 900 mL of water, after which the pH was adjusted with 45% (w/w) KOH to pH 5.0±0.1 and the volume was filled to 1000 mL. The method was then tested for suitability with the SIF, buffer pH 4.5, and SGF regarding precision and linearity. The correlation coefficient of the calibration curve was at least 0.999 for each medium, and the coefficients of variation were 1.68 in SGF, 1.38 in pH 4.5 buffer, and 1.86 in SIF, respectively.
Metronidazole
The analytical quantification for the dissolution samples was changed from the USP 32 procedure. The tablet monograph uses UV absorption at 278 nm for the dissolution test, but the assay uses 254 nm. Metronidazole has another absorption maximum at 228 nm, and this value was used in this study because it resulted in good linearity for drug concentrations between 3.75% and 120% of the expected drug content in 900 mL of medium. The HPLC assay used the following conditions: UV detection at 228 nm and the analytical column was a Lichrospher RP Select B column (12.5×4 mm) (Merck) with a guard column. The mobile phase was water/acetonitrile (66:34). Analysts validated the modified method for suitability with the media in terms of precision and linearity following procedures in USP general chapter Validation of Compendial Procedures <1225>. The correlation coefficient of the calibration curve was at least 0.999 for each medium, and the coefficients of variation were 2.87 in SGF, 0.87 in pH 4.5 buffer, and 2.98 in SIF, respectively.
Zidovudine
The HPLC procedure was modified from that given in USP in order to achieve shorter retention times and used the following conditions: UV detection took place at 265 nm, and the analytical column was a LiChrosphere RP 60 Select B (Merck) with a guard column. The mobile phase was water/ acetonitrile: (72:28). The correlation coefficient of the calibration curve was at least 0.999 for each medium, and the coefficients of variation were 1.49 in SGF, 2.12 in pH 4.5 buffer, and 2.72 in SIF, respectively.
Study Design
The study design required all equipment and personnel to pass the USP Performance Verification Test (PVT) test in general chapter Dissolution <711>. This criterion is important especially when different labs or multiple personnel or equipment are involved in a study. The PVT ensures that any results generated using standard procedures (whether the studies are conducted in one laboratory or several) comply with the compendial standards established for dissolution test procedures. In this study, all analysts, methods, and equipment passed the PVT test.
Selection of the Comparator Pharmaceutical Product
The preferred CPP according to WHO is an innovator product for which quality, safety, and efficacy have been established in a well-regulated country [e.g., a participant in the International Conference on Harmonization (ICH) or an associated country]. If no innovator product can be identified, an alternative CPP can be chosen. Preferred election criteria are: the CPP has approval in ICH or associated countries; it is "prequalified" by WHO; it has extensive documented use in clinical trials reported in peer-reviewed scientific journals; it has a long and unproblematic period of postmarket surveillance; and finally "well-selected comparators" must conform to compendial quality standards when these exist. The authors used FDA's Orange Book to select suitable CPPs (5) . When the study was planned, the Orange Book listed Amoxil tablets (875 mg amoxicillin tablets from GlaxoSmithKline) as the RLD (5). There are two different dose-proportional strengths listed in the Orange Book, 500 and 875 mg. The WHO list of essential medicines uses the 500-mg strength. However, the RLD was no longer available when the study was performed, and at present the Orange Book lists Amoxil tablets under discontinued products. In order to carry out the study, the authors chose Amoxicillin Sandoz as the CPP because this product was listed in the Orange Book as bioequivalent to Amoxil (5). In addition, Sandoz is a global generic manufacturer located in an ICH country as recommended by the WHO guide to identify a well-selected comparator (8) . For metronidazol, Flagyl 500-mg tablets (Searle Pharmaceuticals) were the RLD. For zidovudine, Retrovir 100-mg capsules (GlaxoSmithKline) were the RLD. Accordingly, these products were used as CPPs in this study.
Data Analysis
All dissolution data were evaluated using an Excel spreadsheet, and the results were plotted for each product. If the average dissolution of six samples of a drug product at 15 min exceeded 85% of the labeled drug amount, then no further dissolution tests were performed for this product. If the mean dissolution was below 85% then six additional units were tested, and a dissolution profile for all 12 samples was generated.
The CPP product was compared with each locally purchased product (test product) according to the following criteria: if both products had >85% drug dissolution within 15 min (very rapidly dissolving in WHO terminology), they were considered similar in that medium and a profile comparison was not done. Otherwise the products were compared by the f 2 metric. A comparison was also performed between the different test products when appropriate.
In vitro equivalence between test products and CPP and between test products from the same country was established if the dissolution profiles of a test and the comparator product were similar in all three test media according to the f 2 evaluation or if they were considered similar due to very rapid dissolution.
RESULTS
Amoxicillin
The CPP passed the USP Assay test requirements-USP does not require a content uniformity test for amoxicillin tablets (see the amoxicillin monograph and USP general chapter <905>). The weight variation of all tested amoxicillin products showed tablet weights between 676.6 and 752.9 mg. The observed standard deviations for the products ranged between ±4.6 and ±24. 6 . Figure 1 shows the dissolution behavior of amoxicillin products sold in Argentina vs. data from the CPP. As seen from the figure, amoxicillin is chemically unstable in SGF, and the drug concentration decreased from the first time point until the end of the observation period.
The CPP, Amoxigrand, and Amoxidal products dissolved rapidly in all three media and were considered to be in vitro equivalent. The Telmox, Amixen, and Amox-G products dissolved less than 85% in 15 min in pH 4.5 buffer and SIF and failed the f 2 comparison criterion with the CPP. Amixen and Amox-G products were similar to each other (f 2 =56.6) but neither of them was similar to Telmox (f 2 =32.8 and 41.1 for Amixen and Amox-G, respectively). Telmox, the Sandoz product sold in Argentina, was not in vitro equivalent to the US Sandoz product (500 mg). Figure 2 shows the dissolution of products from Chile compared to the CPP. All products dissolved rapidly in SGF. In buffer pH 4.5 the CPP and Amoxicilina product dissolved rapidly, but Amoxicilina LCh, Amobiotic, and Amoval dissolved less than 85% in 15 min and failed the f 2 comparison with the CPP. However, for Amoxicilina LCh, Ambiotic, and Amoval, the f 2 values were similar. In SIF, only the CPP and Amobiotic product dissolved rapidly. The other products dissolved less than 85% in 15 min, and again Amoxicilina LCh, Ambiotic, and Amoval were not in vitro similar to the CPP but the three products had similar f 2 values. Figure 3 shows the dissolution behavior of products marketed in Peru. The CPP and all generics had similar f 2 values in SGF. Grunamox was found to be in vitro equivalent to the CPP. Amoxicilina and Amoval were similar to each other but not to the CPP. Only 3 of 12 tested amoxicillin products showed in vitro equivalence to the CPP, and thus only these three can be assumed therapeutically equivalent to the CPP.
Metronidazole
The CPP passed the USP assay requirements and the content uniformity test in <905>. The weight variation of all tested metronidazole products showed tablet weights between 697.8 and 771.4 mg. The observed standard deviations for the products ranged between ±2.4 and ±21.4. Figure 4 shows the dissolution behavior of metronidazole products sold in Argentina vs. the CPP. The Flagyl product made by Pharmacia in the USA was the CPP in this study, but Aventis sells their metronidazole product under the same trade name in Argentina and other countries. The Pharmacia and the Aventis products exhibited different dissolution behavior under all test conditions and were not in vitro equivalent. In SGF the CPP and the Colpofilin product dissolved rapidly. The other products required more than 15 min to release 85% of their doses and did not have similar f 2 results compared to the CPP or to each other. In buffer pH 4.5 and SIF, only Ginkan showed similar f 2 results compared to the CPP, and all other products were not similar. None of the four tested products was similar in all three media, and therefore no product showed in vitro equivalence to the CPP. Figure 5 shows the results of the dissolution study of products purchased in Mexico. The CPP dissolved rapidly in SGF. The Flagenase and Flagyl products required 20 and 45 min to release more than 85% of their doses, respectively. In pH 4.5 buffer, Falgenase dissolved rapidly, but the CPP and Flagyl (Sanofi Aventis) required 30 and 60 min to release more than 85% of their doses, respectively. In SIF, the CPP and Flagyl required 45 and 60 min, respectively, to release more than 85% of their contents, but Flagenase dissolved rapidly. None of the tested products showed in vitro equivalence to the CPP and did not display in vitro equivalence to each other. Figure 6 shows the dissolution results from metronidazole products sold in Peru. The CPP, Metron, and Metronidazole Genfar products dissolved rapidly in SGF. In pH 4.5 buffer and SIF, only the metronidazole from Hersil Fig. 1 . Dissolution behavior of the CPP and amoxicillin products marketed in Argentina. The table summarizes the comparison between the CPP and the different products: positive signs (+) denote similarity with the CPP in the specified medium, and negative signs (−) denote the lack of similarity Fig. 2 . Dissolution behavior of the CPP and amoxicillin products marketed in Chile. The table summarizes the comparison between the CPP and the different products: positive signs (+) denote similarity with the CPP in the specified medium, and negative signs (−) denote the lack of similarity showed f 2 values that were similar to those from the CPP. However, this product failed the criteria in SGF and therefore is not equivalent to the CPP. The Flagyl product from Sanofi Aventis had different dissolution behavior compared to the CPP in all media. None of the tested products showed in vitro equivalence to the CPP. Fig. 3 . Dissolution behavior of the CPP and amoxicillin products marketed in Peru. The table summarizes the comparison between the CPP and the different products: positive signs (+) denote similarity with the CPP in the specified medium, and negative signs (−) denote the lack of similarity Fig. 4 . Dissolution behavior of the CPP and metronidazole products marketed in Argentina. The table summarizes the comparison between the CPP and the different products: positive signs (+) denote similarity with the CPP in the specified medium, and negative signs (−) denote the lack of similarity
Zidovudine
The CPP complied with USP specification for assay and uniformity of dosage forms. All other products were tested only for weight variation. The weight variation of all tested zidovudine capsules showed average weights between 272.4 and 321.9 mg. The observed standard deviations for the products ranged between ±3.1 and ±13.6. Figure 7 shows the dissolution behavior of all tested products in all three media. As shown, all investigated products had >85% dissolution 
DISCUSSION
The study showed the challenges of identifying a CPP when the original RLD is no longer available (18) . In this case, the originally listed amoxicillin RLD from the Orange Book was withdrawn from the market while the study was planned, and the Orange Book had not defined a replacement RLD. The researchers selected a CPP using the WHO criteria, as mentioned above. While the study was in progress TEVA's generic product was identified in the Orange Book as the US replacement RLD. Challenges to obtain certain products were observed for individual countries too. For example, GlaxoSmithKline Peru S.A. marketed Amoxil 12 H in Peru, but this amoxicillin product was not commercially available when the study was undertaken. Thus the authors were unable to determine if this product is identical to the US product. GSK did not market amoxicillin tablets in other countries that were included in this study. These cases demonstrate how difficult it can be to identify an appropriate CPP for each country. Furthermore, Sandoz's amoxicillin 500 mg product sold in Argentina did not show in vitro equivalence to Sandoz's US product, which was chosen as the CPP. The excipient content list (Table I) shows that these two products were formulated differently. Sandoz clarified the difference by explaining that "amoxicillin tablets marketed in Argentina were developed as generic medical products for the European Union (EU) market based on the company's bioequivalence study CPA 45/97. In this study, the bioavailability of the generic medicinal product OSPAMOX 750 mg FCT, batch 95362 (Biochemie GmbH, Austria) was compared with the reference medicinal product Clamoxyl 750-mg tablets, batch 96D15/32335 (SmithKlineBeechem Pharma GmbH, Germany). Because the 90% confidence intervals for the primary bioequivalence parameters were within the prespecified limits of 80%-125%, the study demonstrated the bioequivalence of the tested formulations" (Sandoz, personal communication, 2010) .
The Sandoz product sold in Argentina was developed in Europe, and its BE was tested against a European product that has a different strength compared to the US innovator product (Amoxil GSK). This does not imply that these products are substandard but rather that they were developed to match a different CPP. This study shows that different products from different countries may have different in vitro dissolution even if they contain the same drug and strength and are made by the same manufacturer in the same facility. Importantly, this kind of information typically is not publicly available. Except for the Sandoz product, the authors do not know if the other generics tested underwent bioequivalence testing and which CPP was used. This complicates a comparison of amoxicillin products across different countries. The data give a good overview of in vitro product performances, but any comparisons among them must be limited to the in vitro results.
If a product did not show in vitro equivalence to the CPP, the product is not necessarily bioinequivalent. Its bioequivalence could have been documented using one of the several in vivo options. The study results showed that selected products are available and that they demonstrate in vitro equivalence to the chosen CPP. This is particularly important because the CPP Fig. 7 . Dissolution behavior of the CPP and zidovudine products marketed in the Americas. The table summarizes the comparison between the CPP and the different products: positive signs (+) denote similarity with the CPP in the specified medium, and negative signs (−) denote the lack of similarity used in this study presumably was not developed for all climate zones according to ICH (19) .
In the case of metronidazole, the study found that two different products with the same trade name, Flagyl, are marketed in the Americas. The CPP is from G.D. Searle LLC, which is a Pharmacia subsidiary, which in turn is owned by Pfizer. The Sanofi Aventis Flagyl showed different dissolution behavior in all media compared to the Pharmacia product and may not be therapeutically equivalent. The comparison of the Sanofi Aventis products procured in different countries showed that dissolution profiles of the products from Peru and Argentina were similar in SIF and SGF but not in buffer pH 4.5 (f 2 =43.4; graph not shown). These differences were not linked to the differences in their expiration dates (see Table II ). All three batches were produced in the same factory as stated on the packages and were imported from Mexico to Argentina and Peru. This suggests a more general question about how many batches of a CPP should be investigated before it can be used as CPP in a biowaiver study. There is currently no requirement by any FDA, European, or WHO bioequivalence guidance document to investigate different batches for in vivo bioequivalence studies. These results suggest another question: Can a CPP be used for a biowaiver study if three batches were found not to have in vitro equivalence?
The study hypothesis was confirmed only for the zidovudine products, which showed in vitro equivalence to each other and the CPP. Supplemental Fig. 1 shows two GSK Retrovir products manufactured in the USA and England (purchased in Mexico). The product manufactured in England has a seal between the cap and the capsule body (blue strip). The seal is necessary because of the products' different packaging. The blister pack of the US product must be peeled open at the edges to dispense the capsule, but the sealed capsule of the product made in England must be forced through the aluminum foil of the blister. If the US product is forced through the back liner of its blister, the capsule might dent or break with spillage of contents because of the tensile strength of the back foil. Because the product made in England is exposed to higher forces when it is pressed through the back liner of its blister, the capsule's cap and body must be sealed to prevent spilling. This shows that different regions in the world may require different packaging for the same product, and this can cause adjustments in the dosage forms, as seen for Retrovir. However, as seen from the dissolution profiles for these products, the additional seal did not influence the in vitro performance of the product.
Supplemental Fig. 2 shows a blister pack of a generic product available in Argentina and Uruguay. The capsules were not manufactured properly, and some drug spilled out of the capsules. Several blisters of this product contained one or two capsules that showed this defect. None of the defective capsules were used for the dissolution study. During manufacturing and packaging, visual quality control should have removed such blisters before batch release. Another observation is that these capsules use the same type of blister as the Retrovir capsules made in England. However, these capsules have no seal between capsule body and cap to avoid content spillage when the capsules are pressed through the blister. The aluminum foils were determined to be 0.04 mm for the Retrovir blister and 0.03 mm for the generic, which might explain the addition of the seal between cap and body when a thicker blister foil is used.
CONCLUSIONS
All tested zidovudine products showed in vitro equivalence to each other and the CPP. Only 3 of 12 tested amoxicillin products showed in vitro equivalence to the CPP. None of the tested metronidazole products exhibited in vitro equivalence to the CPP. Two different metronidazole products with the same trade name are marketed globally. These products have different biopharmaceutical properties and were not in vitro equivalent.
As advocated by WHO and others, the issues and challenges in identifying a CPP in different countries clearly suggest the potential value for establishing an international reference standard product to support bioequivalence studies. Working with such a product, the generic industry in developing countries could use an internationally accepted reference standard to develop therapeutically equivalent and thus interchangeable multisource products. Innovator manufacturers would also be able to use such a product to compare selected formulations. At this time, clinicians should generally avoid assumptions that formulations sold across national boundaries are therapeutically equivalent, even when labeled to contain the same drug substance and strength.
